Ophthotech Corporation Reports Second Quarter 2015 Financial And Operating Results
NEW YORK--(BUSINESS WIRE)--Ophthotech Corporation (Nasdaq:OPHT) today announced financial results for the second quarter ended June 30, 2015 and provided an update on the Company’s business and product development programs.
Program Highlights
In May 2015, Ophthotech provided updates on the Company’s two Phase 3 trials of Fovista® in combination with Lucentis® (ranibizumab) in patients with wet Age-Related Macular Degeneration (AMD).
Help employers find you! Check out all the jobs and post your resume.
Program Highlights
In May 2015, Ophthotech provided updates on the Company’s two Phase 3 trials of Fovista® in combination with Lucentis® (ranibizumab) in patients with wet Age-Related Macular Degeneration (AMD).
Help employers find you! Check out all the jobs and post your resume.